Morphogenesis Seeks Skin Cancer Patients for New Clinical Trials

Known for developing personalized immunotherapies for the treatment of cancer through novel cell and gene therapies, UF startup and UF Innovate | Sid Martin Biotech alumni company Morphogenesis, Inc., has received FDA approval to expand its human clinical trials into two more types of cancer. Using its ImmuneFx (IFx) cancer vaccine technology that initiates the power of the immune system on the destruction of tumor cells, Morphogenesis will focus the newly approved trials on advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Clinical trials need patients. To qualify for the upcoming trials, someone must have been diagnosed with advanced Merkel or cutaneous squamous cell carcinoma and have failed or refused other therapies, Dr. Patricia Lawman, CEO of Morphogenesis says.

Learn more about Morphogenesis Seeks Skin Cancer Patients for New Clinical Trials.